Tecentriq - direct healthcare professional communication (DHPC)

atezolizumab

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC): Tecentriq (atezolizumab): Risk of Severe Cutaneous Adverse Reactions (SCARs)

Key facts

• Medicine name:
  Tecentriq
• Active substance:
  atezolizumab
• Therapeutic area (MeSH):
  • Carcinoma, Transitional Cell
  • Carcinoma, Non-Small-Cell Lung
  • Urologic Neoplasms
  • Breast Neoplasms
  • Small Cell Lung Carcinoma
• Procedure number:
  EMEA/H/C/00414/II/0054
• Regulatory outcome:
  Variation
• DHPC type:
  Adverse event
• Human ATC codes:
  L01FX06
• Dissemination date:
  25/03/2021